Stock Research: GSK

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

GSK

LSE:GSK GB0009252882
48
  • Value
    86
  • Growth
    71
  • Safety
    Safety
    8
  • Combined
    56
  • Sentiment
    47
  • 360° View
    360° View
    48
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

GSK plc is a global biopharma company focused on developing medicines and vaccines. It operates in the pharmaceuticals industry, with a focus on respiratory, immunology, oncology, HIV, and infectious diseases. GSK's operations are global. In the last fiscal year, the company had a market cap of $76,670 million, profits of $28,223 million, and revenue of $39,254 million, with 68629 employees.

more

ANALYSIS: With an Obermatt 360° View of 48 (better than 48% compared with alternatives), overall professional sentiment and financial characteristics for the stock GSK are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for GSK. The consolidated Value Rank has an attractive rank of 86, which means that the share price of GSK is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 86% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 71, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 47. Professional investors are more confident in 53% other stocks. Worryingly, the company has risky financing, with a Safety rank of 8. This means 92% of comparable companies have a safer financing structure than GSK. ...read more

more
Index
FTSE All Shares
FTSE 100
FTSE 350
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
86 88 89 86
Growth
71 16 55 21
Safety
Safety
8 20 8 1
Sentiment
47 69 70 16
360° View
360° View
48 54 63 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
7 13 19 33
Opinions Change
50 81 71 16
Pro Holdings
n/a 87 80 78
Market Pulse
44 52 65 25
Sentiment
47 69 70 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
86 88 89 86
Growth
71 16 55 21
Safety Safety
8 20 8 1
Combined
56 38 46 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
60 50 67 85
Price vs. Earnings (P/E)
67 91 89 87
Price vs. Book (P/B)
48 20 26 34
Dividend Yield
91 96 96 92
Value
86 88 89 86
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
28 42 39 37
Profit Growth
92 38 58 23
Capital Growth
65 17 64 6
Stock Returns
58 32 52 78
Growth
71 16 55 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
17 13 6 7
Refinancing
10 11 9 1
Liquidity
63 71 45 41
Safety Safety
8 20 8 1

Similar Stocks

Discover high‑ranked alternatives to GSK and broaden your portfolio horizons.

ZIGUP

LSE:ZIG
Country: United Kingdom
Industry: Specialized Consumer Services
Size: Medium
Full Stock Analysis

Pan African

LSE:PAF
Country: United Kingdom
Industry: Gold Production
Size: Medium
Full Stock Analysis

Costain

LSE:COST
Country: United Kingdom
Industry: Construction & Engineering
Size: Medium
Full Stock Analysis

Ipsen

PAR:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a mixed bag with good value and high growth balanced by risky financing and negative sentiment. This is a risky stock that requires conviction; you should only consider it if you are willing to conduct further research into the underlying sentiment and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: